Literature DB >> 29848070

Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research.

Bruce A Feinberg1, Murtuza Bharmal2, Andrew J Klink1, Chadi Nabhan1, Hemant Phatak3.   

Abstract

AIM: Real-world evidence of charted treatment responses to cancer drug therapy was compared with medical record derived radiographic measurements of target lesions per Response Evaluation Criteria in Solid Tumors (RECIST). MATERIALS &
METHODS: 15 physicians treating 59 metastatic Merkel cell cancer (mMCC) patients contributed patient-level data. A comparison of medical record reported best response with radiographic measurements per RECIST of pre- and post-treatment target lesions.
RESULTS: RECIST response rates were significantly lower compared with medical record reported with a concordance of 43.2% (95% CI: 28.0-58.4%).
CONCLUSION: Subjective assessment of tumor response collected via traditional chart abstraction may overestimate benefit and limit the potential role of real-world evidence in value-based care research. The use of target lesion measurements presents an attractive alternative that better aligns with trial results.

Entities:  

Keywords:  clinical response assessment; electronic case report forms; metastatic Merkel cell carcinoma; real-world evidence

Mesh:

Substances:

Year:  2018        PMID: 29848070     DOI: 10.2217/fon-2018-0317

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  5 in total

1.  Synchronous tumours detected during cancer patient staging: prevalence and patterns of occurrence in multidetector computed tomography.

Authors:  Antonio Corvino; Sergio Venanzio Setola; Fabio Sandomenico; Fabio Corvino; Orlando Catalano
Journal:  Pol J Radiol       Date:  2020-05-26

2.  Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC.

Authors:  Xinran Ma; Lawrence Bellomo; Kelly Magee; Caroline S Bennette; Olga Tymejczyk; Meghna Samant; Melisa Tucker; Nathan Nussbaum; Bryan E Bowser; Joshua S Kraut; Ariel Bulua Bourla
Journal:  Adv Ther       Date:  2021-03-05       Impact factor: 3.845

3.  Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.

Authors:  Bruce A Feinberg; Marjorie E Zettler; Andrew J Klink; Choo H Lee; Ajeet Gajra; Jonathan K Kish
Journal:  JAMA Netw Open       Date:  2021-02-01

4.  Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non-Small Cell Lung Cancer Treated With First-Line Therapy.

Authors:  Xinran Ma; Lawrence Bellomo; Ian Hooley; Tori Williams; Meghna Samant; Katherine Tan; Brian Segal; Ariel Bulua Bourla
Journal:  JAMA Netw Open       Date:  2022-05-02

5.  A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL).

Authors:  Gilles Salles; Stephen J Schuster; Luca Fischer; John Kuruvilla; Piers E M Patten; Bastian von Tresckow; Sonali Smith; Ana Jiménez Ubieto; Keith L Davis; Saurabh Nagar; Jie Zhang; Vamsi Bollu; Etienne Jousseaume; Roberto Ramos; Yucai Wang; Brian K Link
Journal:  Hemasphere       Date:  2022-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.